HRS-5041 is named as an intervention in 5 current clinical trials in our China register. 4 are recruiting patients now. The most common phase is Phase 1/2. The sponsor with the most trials is Jiangsu HengRui Medicine Co., Ltd (3). The most-studied condition is Prostate Cancer.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
NCT06568094 · ClinicalTrials.gov ↗ · Prostate Cancer
|
Phase 1/2 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | China |
|
A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer
NCT07407283 · ClinicalTrials.gov ↗ · Prostate Cancer
|
Phase 1/2 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | China |
|
Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT05942001 · ClinicalTrials.gov ↗ · Advanced Prostate Cancer
|
Phase 1 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | China |
|
Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer
NCT07115446 · ClinicalTrials.gov ↗ · Advanced Prostate Cancer
|
Phase 1 | Recruiting | Hansoh BioMedical R&D Company | China |
|
Study of HRS-2189 Combined HRS-5041 in Prostate Cancer
NCT06738745 · ClinicalTrials.gov ↗ · Prostate Cancer Metastatic Disease
|
Phase 2 | Not yet open | Fudan University | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Jiangsu HengRui Medicine Co., Ltd. | 3 |
| Fudan University | 1 |
| Hansoh BioMedical R&D Company | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 5 | 4 |
A trial with sites in more than one country appears in each of those registers.
5 current trials in our China register name HRS-5041 as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 4 of the 5 trials are recruiting: 4 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Jiangsu HengRui Medicine Co., Ltd (3), Fudan University (1) and Hansoh BioMedical R&D Company (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how HRS-5041 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how HRS-5041 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists HRS-5041 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.